Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Vit Georgia Parmi | Pharma | 14.0% | 48th pct | 110 |
| Med Parmasi Group | Pharma | -0.9% | 14th pct | 110 |
| Pip Company | Pharma | -15.5% | 3rd pct | 110 |
| Medimex | Pharma | — | no FY data | 110 |
| Sando Pharma | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 3 of 5 peers filed FY2024. Switch to FY2018 (5 of 5).
| Ratio — FY 2024 | Pip Company | Med Parmasi Group | Vit Georgia Parmi | Medimex | Sando Pharma |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 8.0% | 36.5% | 37.3% | — | — |
| EBITDA Margin | -15.5% | -0.9% | 14.0% | — | — |
| EBITDAR | -188 | -11 | 170 | — | — |
| EBITDAR Margin | -14.7% | -0.9% | 16.6% | — | — |
| EBIT Margin | -15.6% | -6.1% | 12.8% | — | — |
| Net Profit Margin | -24.2% | -4.1% | 12.8% | — | — |
| Operating Expense % of Sales | 23.6% | 37.5% | 23.4% | — | — |
| Returns | |||||
| Return on Assets (ROA) | -9.2% | -5.4% | 10.6% | — | — |
| Return on Equity (ROE) | N/A | -7.2% | 25.4% | — | — |
| ROIC [EBIT / Invested Capital] | N/A | -10.7% | 12.6% | — | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 3.1% | 42.9% | — | — |
| Debt-to-Equity | -0.00x | 0.04x | 1.02x | — | — |
| Debt-to-EBITDA | N/A | N/A | 3.70x | — | — |
| Equity-to-Assets | -47.2% | 75.3% | 41.9% | — | — |
| Net Debt | -3 | 7 | 523 | — | — |
| Cash & Equivalents | 3 | 21 | 6 | — | — |
| Total Debt | N/A | 28 | 528 | — | — |
| Liquidity & working capital | |||||
| Current Ratio | 0.68x | 3.03x | 4.37x | — | — |
| Quick Ratio | 0.68x | 3.03x | 4.37x | — | — |
| Cash Ratio | 0.00x | 0.10x | 0.04x | — | — |
| Total Current Assets | 3,360 | 637 | 664 | — | — |
| Total Current Liabilities | 4,920 | 210 | 152 | — | — |
| Inventory | N/A | N/A | N/A | — | — |
| Trade Receivables | 2,662 | 340 | 550 | — | — |
| Trade Payables | 4,920 | 94 | 146 | — | — |
| Net Working Capital | -1,560 | 427 | 512 | — | — |
| Net Working Capital % of Revenue | -122.2% | 36.0% | 50.1% | — | — |
| Trade Working Capital | -2,258 | 246 | 404 | — | — |
| Trade Working Capital % of Revenue | -176.9% | 20.7% | 39.5% | — | — |
| Change in Trade Working Capital | N/A | N/A | N/A | — | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | — | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | — | — |
| Receivables Turnover | 0.48x | 3.49x | 1.86x | — | — |
| Days Sales Outstanding (DSO) | 761.2 | 104.7 | 196.3 | — | — |
| Payables Turnover | 0.24x | 7.98x | 4.39x | — | — |
| Days Payable Outstanding (DPO) | 1529.5 | 45.7 | 83.1 | — | — |
| Cash Conversion Cycle | -768.3 days | 59.0 days | 113.2 days | — | — |
| Asset Turnover | 0.38x | 1.33x | 0.83x | — | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | N/A | 9 | 5 | — | — |
| Free Cash Flow (OCF − Capex proxy) | N/A | 9 | 5 | — | — |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | 3.8% | — | — |
| Dividends Declared | N/A | N/A | N/A | — | — |
| Dividend Payout Ratio | N/A | N/A | N/A | — | — |